ANN ARBOR, Mich., Feb. 10, 2010 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous cellular therapies for the treatment of severe, chronic cardiovascular diseases, today reported financial results for its second fiscal quarter ended December 31, 2009, and also announced progress in its late-stage clinical development programs and corporate operations.
